BioNexus Gene Lab (BGLC) Competitors

BioNexus Gene Lab logo
$0.68 -0.05 (-7.29%)
Closing price 03:59 PM Eastern
Extended Trading
$0.68 -0.01 (-0.74%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BGLC vs. CLWT, INEO, MWG, BGMS, and SOS

Should you buy BioNexus Gene Lab stock or one of its competitors? BioNexus Gene Lab's main competitors and comparable companies include Euro Tech (CLWT), INNEOVA (INEO), Multi Ways (MWG), Cyclacel Pharmaceuticals (BGMS), and SOS (SOS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "trading companies & distributors" industry.

How does BioNexus Gene Lab compare to Euro Tech?

BioNexus Gene Lab (NASDAQ:BGLC) and Euro Tech (NASDAQ:CLWT) are both small-cap industrials companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

Euro Tech has higher revenue and earnings than BioNexus Gene Lab.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioNexus Gene Lab$7.43M0.27-$2.98M-$1.26N/A
Euro Tech$13.27M0.63$160KN/AN/A

In the previous week, BioNexus Gene Lab had 2 more articles in the media than Euro Tech. MarketBeat recorded 2 mentions for BioNexus Gene Lab and 0 mentions for Euro Tech. BioNexus Gene Lab's average media sentiment score of 0.00 equaled Euro Tech'saverage media sentiment score.

Company Overall Sentiment
BioNexus Gene Lab Neutral
Euro Tech Neutral

Euro Tech has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -82.38%. Euro Tech's return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company Net Margins Return on Equity Return on Assets
BioNexus Gene Lab-82.38% -32.92% -29.75%
Euro Tech N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioNexus Gene Lab
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Euro Tech
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

18.9% of BioNexus Gene Lab shares are owned by institutional investors. Comparatively, 2.9% of Euro Tech shares are owned by institutional investors. 0.1% of BioNexus Gene Lab shares are owned by company insiders. Comparatively, 79.0% of Euro Tech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BioNexus Gene Lab has a beta of 4.28, indicating that its stock price is 328% more volatile than the broader market. Comparatively, Euro Tech has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market.

Summary

Euro Tech beats BioNexus Gene Lab on 8 of the 11 factors compared between the two stocks.

How does BioNexus Gene Lab compare to INNEOVA?

BioNexus Gene Lab (NASDAQ:BGLC) and INNEOVA (NASDAQ:INEO) are both small-cap industrials companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

INNEOVA has higher revenue and earnings than BioNexus Gene Lab.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioNexus Gene Lab$7.43M0.27-$2.98M-$1.26N/A
INNEOVA$58.42M0.11-$400KN/AN/A

BioNexus Gene Lab has a beta of 4.28, suggesting that its share price is 328% more volatile than the broader market. Comparatively, INNEOVA has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

In the previous week, BioNexus Gene Lab had 1 more articles in the media than INNEOVA. MarketBeat recorded 2 mentions for BioNexus Gene Lab and 1 mentions for INNEOVA. BioNexus Gene Lab's average media sentiment score of 0.00 equaled INNEOVA'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioNexus Gene Lab
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
INNEOVA
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioNexus Gene Lab
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
INNEOVA
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

INNEOVA has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -82.38%. INNEOVA's return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company Net Margins Return on Equity Return on Assets
BioNexus Gene Lab-82.38% -32.92% -29.75%
INNEOVA N/A N/A N/A

18.9% of BioNexus Gene Lab shares are held by institutional investors. 0.1% of BioNexus Gene Lab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

BioNexus Gene Lab and INNEOVA tied by winning 5 of the 10 factors compared between the two stocks.

How does BioNexus Gene Lab compare to Multi Ways?

BioNexus Gene Lab (NASDAQ:BGLC) and Multi Ways (NYSE:MWG) are both small-cap industrials companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

Multi Ways has higher revenue and earnings than BioNexus Gene Lab.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioNexus Gene Lab$7.43M0.27-$2.98M-$1.26N/A
Multi Ways$44.77M0.13$1.79MN/AN/A

In the previous week, BioNexus Gene Lab had 1 more articles in the media than Multi Ways. MarketBeat recorded 2 mentions for BioNexus Gene Lab and 1 mentions for Multi Ways. BioNexus Gene Lab's average media sentiment score of 0.00 beat Multi Ways' score of -0.91 indicating that BioNexus Gene Lab is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioNexus Gene Lab
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Multi Ways
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative

Multi Ways has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -82.38%. Multi Ways' return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company Net Margins Return on Equity Return on Assets
BioNexus Gene Lab-82.38% -32.92% -29.75%
Multi Ways N/A N/A N/A

BioNexus Gene Lab has a beta of 4.28, indicating that its share price is 328% more volatile than the broader market. Comparatively, Multi Ways has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioNexus Gene Lab
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Multi Ways
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

18.9% of BioNexus Gene Lab shares are held by institutional investors. Comparatively, 0.8% of Multi Ways shares are held by institutional investors. 0.1% of BioNexus Gene Lab shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

BioNexus Gene Lab beats Multi Ways on 7 of the 12 factors compared between the two stocks.

How does BioNexus Gene Lab compare to Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap industrials companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Cyclacel Pharmaceuticals has a net margin of -74.40% compared to BioNexus Gene Lab's net margin of -82.38%. Cyclacel Pharmaceuticals' return on equity of -24.24% beat BioNexus Gene Lab's return on equity.

Company Net Margins Return on Equity Return on Assets
Cyclacel Pharmaceuticals-74.40% -24.24% -21.39%
BioNexus Gene Lab -82.38%-32.92%-29.75%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclacel Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
BioNexus Gene Lab
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

BioNexus Gene Lab has higher revenue and earnings than Cyclacel Pharmaceuticals. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cyclacel Pharmaceuticals$750K5.39-$3M-$2.40N/A
BioNexus Gene Lab$7.43M0.27-$2.98M-$1.26N/A

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 18.9% of BioNexus Gene Lab shares are held by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of BioNexus Gene Lab shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cyclacel Pharmaceuticals has a beta of -0.44, indicating that its share price is 144% less volatile than the broader market. Comparatively, BioNexus Gene Lab has a beta of 4.28, indicating that its share price is 328% more volatile than the broader market.

In the previous week, Cyclacel Pharmaceuticals and Cyclacel Pharmaceuticals both had 2 articles in the media. BioNexus Gene Lab's average media sentiment score of 0.00 beat Cyclacel Pharmaceuticals' score of -0.50 indicating that BioNexus Gene Lab is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cyclacel Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative
BioNexus Gene Lab
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Cyclacel Pharmaceuticals beats BioNexus Gene Lab on 6 of the 11 factors compared between the two stocks.

How does BioNexus Gene Lab compare to SOS?

SOS (NYSE:SOS) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap industrials companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

BioNexus Gene Lab has lower revenue, but higher earnings than SOS.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SOS$154.29M0.02-$97.32MN/AN/A
BioNexus Gene Lab$7.43M0.27-$2.98M-$1.26N/A

SOS has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -82.38%. SOS's return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company Net Margins Return on Equity Return on Assets
SOSN/A N/A N/A
BioNexus Gene Lab -82.38%-32.92%-29.75%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SOS
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
BioNexus Gene Lab
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

1.9% of SOS shares are held by institutional investors. Comparatively, 18.9% of BioNexus Gene Lab shares are held by institutional investors. 2.7% of SOS shares are held by insiders. Comparatively, 0.1% of BioNexus Gene Lab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

SOS has a beta of 2.72, indicating that its stock price is 172% more volatile than the broader market. Comparatively, BioNexus Gene Lab has a beta of 4.28, indicating that its stock price is 328% more volatile than the broader market.

In the previous week, SOS and SOS both had 2 articles in the media. SOS's average media sentiment score of 0.00 equaled BioNexus Gene Lab'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SOS
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BioNexus Gene Lab
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

SOS beats BioNexus Gene Lab on 5 of the 9 factors compared between the two stocks.

Get BioNexus Gene Lab News Delivered to You Automatically

Sign up to receive the latest news and ratings for BGLC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGLC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BGLC vs. The Competition

MetricBioNexus Gene LabTrading Companies & Distributors IndustryIndustrials SectorNASDAQ Exchange
Market Cap$2.15M$9.56B$9.83B$11.70B
Dividend YieldN/A3.53%2.95%4.65%
P/E Ratio-0.5436.5729.9326.67
Price / Sales0.271.422.915.53
Price / CashN/A28.0019.7221.66
Price / Book0.193.103.633.65
Net Income-$2.98M$374.26M$612.75M$394.00M
7 Day Performance-19.81%-3.86%-4.27%-6.39%
1 Month Performance-44.49%-4.38%-4.19%-8.77%
1 Year Performance-85.80%9.18%0.73%-8.47%

BioNexus Gene Lab Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BGLC
BioNexus Gene Lab
0.4815 of 5 stars
$0.68
-7.3%
N/A-84.8%$2.15M$7.43MN/A19
CLWT
Euro Tech
1.1139 of 5 stars
$1.20
-0.8%
N/A-0.5%$8.94M$13.27MN/A47
INEO
INNEOVA
0.3679 of 5 stars
$0.60
+0.8%
N/A-27.7%$7.26M$58.42MN/AN/A
MWG
Multi Ways
N/A$1.39
-4.1%
N/A-43.5%$7.14M$44.77MN/A92
BGMS
Cyclacel Pharmaceuticals
0.9417 of 5 stars
$0.73
+8.5%
N/AN/A$4.82M$1.86MN/A12

Related Companies and Tools


This page (NASDAQ:BGLC) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners